Levosimendan 141505-33-1

简要描述：Levosimendan 141505-33-1
Levosimendan is a calcium sensitizer used in the management of acutely decompensated congestive heart failure.

产品型号：abs47028070
厂商性质：生产厂家
更新时间：2026-01-15
访问量：615

产品咨询联系我们

Product Category

生化试剂

其它生化试剂植物提取物碳水化合物生物缓冲剂荧光探针与染料表面活性剂酶&辅酶&酶底物蛋白质组学动植物激素小分子化合物生化检测试剂盒逆行示踪剂抗生素核苷&核苷酸多肽

品牌	absin	CAS	141505-33-1
分子式	C14H12N6O	纯度	99%
分子量	280.28	货号	abs47028070
规格	25mg	供货周期	现货
主要用途	used in the management of acutely decomp	应用领域	化工,生物产业,农林牧渔,制药/生物制药,综合

Levosimendan 141505-33-1

产品描述
描述	Levosimendan is a calcium sensitizer used in the management of acutely decompensated congestive heart failure. It increases the sensitivity of the heart to calcium, thus increasing cardiac contractility without a rise in intracellular calcium. Levosimendan exerts its effect by increasing calcium sensitivity of myocytes by binding to cardiac troponin C in a calcium-dependent manner.
纯度	99%
储存/保存方法	Store at -20℃ for one year（Powder）；Store at 2-4℃ for two weeks；Store at -20℃ for six months after dissolution.
基本信息
别名	左xi孟旦；OR1259
外观	yellow
可溶性/溶解性	DMSO : 52 mg/mL (185.5 mM)
生物活性
靶点	Cardiac troponin C
In vitro(体外研究)	Levosimendan is a calcium sensitizer acting through calcium-dependent binding to cardiac troponin C (cTnC). Levosimendan at 3 μM decreases the value of Ca50 from 2.73μM to 1.19 μM. levosimendan exhibits its calcium sensitizing effect through calcium-dependent binding to the N-terminal domain of cTnC. Levosimendan significantly hyperpolarizes resting potential of rat mesenteric arterial myocytes with an EC50 of 2.9 μM and maximal effect (19.5 mV) at 10 μM, probably through activation of a glibenclamide-sensitive K+ channel. Levosimendan has inotropic and lusitropic actions in failing human myocardium, with average maximum increase in twitch tension of 47% at a levosimendan concentration of 0.8 μM. Levosimendan causes rapid dose-dependent improvement in hemodynamic function in patients with decompensated heart failure.
In vivo(体内研究)	Levosimendan at low concentrations (0.03 to 0.1 μM) acts preferably as a Ca2+ sensitizer, whereas at higher concentrations (0.1 to 0.3 μmol/L) its action as a phosphodiesterase inhibitor contributes to the positive inotropic effect.
参考文献
参考文献	1. Haikala H, J Mol Cell Cardiol, 1995, 27(9), 1859-1866. 2. Yokoshiki H, Eur J Pharmacol, 1997, 333(2-3), 249-259.

研究领域
研究领域	Cardiovascular Drug DiscoverySmall Molecule DrugLead Compound Discovery

Levosimendan 141505-33-1温馨提示：本产品仅作科研实验使用，不支持临床等研究

上一篇：abs47028069Latanoprost 130209-82-4
下一篇：abs47028072aAlcaftadine 147084-10-4

Levosimendan 141505-33-1

留言框

产品：

您的单位：

您的姓名：

联系电话：

常用邮箱：

省份：

详细地址：

补充说明：

验证码：